NCCN Guidelines® Insights: Melanoma: Cutaneous, version 2.2021: Featured updates to the NCCN Guidelines Guidelines


Authors: Swetter, S. M.; Thompson, J. A.; Albertini, M. R.; Barker, C. A.; Baumgartner, J.; Boland, G.; Chmielowski, B.; DiMaio, D.; Durham, A.; Fields, R. C.; Fleming, M. D.; Galan, A.; Gastman, B.; Grossmann, K.; Guild, S.; Holder, A.; Johnson, D.; Joseph, R. W.; Karakousis, G.; Kendra, K.; Lange, J. R.; Lanning, R.; Margolin, K.; Olszanski, A. J.; Ott, P. A.; Ross, M. I.; Salama, A. K.; Sharma, R.; Skitzki, J.; Sosman, J.; Wuthrick, E.; McMillian, N. R.; Engh, A. M.
Title: NCCN Guidelines® Insights: Melanoma: Cutaneous, version 2.2021: Featured updates to the NCCN Guidelines
Abstract: Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been expanded to include pathways for treatment of microscopic satellitosis (added in v2.2020), and the following Principles sections: Molecular Testing (added in v2.2019), Systemic Therapy Considerations (added in v2.2020), and Brain Metastases Management (added in v3.2020). The v1.2021 update included additional modifications of these sections and notable revisions to Principles of: Pathology, Surgical Margins for Wide Excision of Primary Melanoma, Sentinel Lymph Node Biopsy, Completion/Therapeutic Lymph Node Dissection, and Radiation Therapy. These NCCN Guidelines Insights discuss the important changes to pathology and surgery recommendations, as well as additions to systemic therapy options for patients with advanced disease.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 19
Issue: 4
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2021-04-01
Start Page: 364
End Page: 376
Language: English
DOI: 10.6004/jnccn.2021.0018
PUBMED: 33845460
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 3 May 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Christopher Barker
    218 Barker